Bilun Gemicioğlu1, Dilşad Mungan2, Sevim Bavbek2, Füsun Yıldız3, Mehmet Polatlı4, Sibel Naycı5, Ferda Öner Erkekol6, Hatice Türker7, Hakan Günen7, Güngor Çamsarı8, Öznur Abadoğlu9, Arif Çımrın10, A Berna Dursun11, Özlem Göksel12, Seçil Kepil Özdemir13, Şermin Börekci1, Ömür Aydın2, Birsen Ocaklı7, Aygün Gür8, Arzu Baygul14, Zeynep Mısırlıgil2. 1. Department of Pulmonary Diseases, İstanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, İstanbul, Turkey. 2. Department of Pulmonary Diseases, Division of Allerrgy and Immunology, Ankara University School of Medicine, Ankara, Turkey. 3. Department of Pulmonary Diseases, Kocaeli University School of Medicine, Kocaeli, Turkey. 4. Department of Pulmonary Diseases, Adnan Menderes University School of Medicine, Aydın, Turkey. 5. Department of Pulmonary Diseases, Mersin University School of Medicine, Mersin, Turkey. 6. Ataturk Chest Diseases and Thoracic Surgery Education and Research Hospital, Ankara, Turkey. 7. Süreyyapasa Chest Diseases and Thoracic Surgery Education and Research Hospital, İstanbul, Turkey. 8. Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, İstanbul, Turkey. 9. Department of Pulmonary Diseases, Cumhuriyet University School of Medicine, Sivas, Turkey. 10. Department of Pulmonary Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey. 11. Department of Internal Medicine, Division of Allergy and Immunology, Recep Tayip Erdoğan University School of Medicine, Rize, Turkey. 12. Department of Pulmonary Diseases, Division of Allerrgy and Immunology, Ege University School of Medicine, İzmir, Turkey. 13. Dışkapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey. 14. Department of Biostatistics, Beykent University, İstanbul, Turkey.
Abstract
OBJECTIVES: A multicenter trial was designed to validate the "Assessment Tools for Asthma (ATA)" questionnaire, a newly developed questionnaire, which evaluates both asthma control and risk factors associated with asthma control with a single instrument. MATERIALS AND METHODS: This cross-sectional study involved 810 cases from 14 clinics in 9 Turkish cities. The ATA questionnaire and Asthma Control Test (ACT) were administered. The Visual Analog Scale (VAS) was used to evaluate the control status of 100 randomized cases. ATA is an eight-item physician-administered questionnaire. It comprises the following two sections-ATA1, assesses symptomatic control criteria, and the remaining section, queries the flare-up of asthma, control of comorbidities, treatment adherence, and inhaler technique. RESULTS: The mean scores for ATA1, ATA total, VAS, and ACT were 24.7±14.8, 53.8±19, 7.1±3, and 18.8±5.5, respectively. According to the ATA questionnaire, among all patients, 34.3% had controlled, 18.8% had partly controlled, and 46.9% had uncontrolled asthma. Furthermore, 16.6% patients had flare-ups between visits, 96.4% patients had uncontrolled comorbidity, 17% patients had irregular asthma treatment, and only 8.4% patients used the incorrect inhaler technique. The ATA questionnaire showed internal consistency (Cronbach's alpha coefficient=0.683). ACT, ATA1, and two specialists' evaluations using VAS correlated strongly with the ATA total scores (Spearman correlation coefficient (r) values: 0.776, 0.783, and 0.909, respectively; p-values: p<0.001, p<0.001, and p<0.001, respectively). According to Receiver Operating Characteristic analysis, the cut-off value of ATA was 50 (sensitivity=84.4%, specificity=82.40%). CONCLUSION: The validated ATA questionnaire may be a practical tool for physicians in asthma management.
OBJECTIVES: A multicenter trial was designed to validate the "Assessment Tools for Asthma (ATA)" questionnaire, a newly developed questionnaire, which evaluates both asthma control and risk factors associated with asthma control with a single instrument. MATERIALS AND METHODS: This cross-sectional study involved 810 cases from 14 clinics in 9 Turkish cities. The ATA questionnaire and Asthma Control Test (ACT) were administered. The Visual Analog Scale (VAS) was used to evaluate the control status of 100 randomized cases. ATA is an eight-item physician-administered questionnaire. It comprises the following two sections-ATA1, assesses symptomatic control criteria, and the remaining section, queries the flare-up of asthma, control of comorbidities, treatment adherence, and inhaler technique. RESULTS: The mean scores for ATA1, ATA total, VAS, and ACT were 24.7±14.8, 53.8±19, 7.1±3, and 18.8±5.5, respectively. According to the ATA questionnaire, among all patients, 34.3% had controlled, 18.8% had partly controlled, and 46.9% had uncontrolled asthma. Furthermore, 16.6% patients had flare-ups between visits, 96.4% patients had uncontrolled comorbidity, 17% patients had irregular asthma treatment, and only 8.4% patients used the incorrect inhaler technique. The ATA questionnaire showed internal consistency (Cronbach's alpha coefficient=0.683). ACT, ATA1, and two specialists' evaluations using VAS correlated strongly with the ATA total scores (Spearman correlation coefficient (r) values: 0.776, 0.783, and 0.909, respectively; p-values: p<0.001, p<0.001, and p<0.001, respectively). According to Receiver Operating Characteristic analysis, the cut-off value of ATA was 50 (sensitivity=84.4%, specificity=82.40%). CONCLUSION: The validated ATA questionnaire may be a practical tool for physicians in asthma management.
Authors: Wenjia Chen; Larry D Lynd; J Mark FitzGerald; Carlo A Marra; Robert Balshaw; Teresa To; Hamid Tavakoli; Mohsen Sadatsafavi Journal: Eur Respir J Date: 2016-10-06 Impact factor: 16.671
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Michael Schatz; Christine A Sorkness; James T Li; Philip Marcus; John J Murray; Robert A Nathan; Mark Kosinski; Trudy B Pendergraft; Priti Jhingran Journal: J Allergy Clin Immunol Date: 2006-03 Impact factor: 10.793
Authors: Mike Thomas; Stephen Kay; James Pike; Angela Williams; Jacqueline R Carranza Rosenzweig; Elizabeth V Hillyer; David Price Journal: Prim Care Respir J Date: 2009-03